Americans are flocking to new weight loss medications like Novo Nordisk’s Wegovy and Eli Lilly's Zepbound, which work by ...

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy.

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...

Eli Lilly & Co has experienced a significant stock price decline of 18.64% over the past week, largely due to disappointing ...

Beyond weight loss, semaglutide has also shown potential benefits for cardiovascular health, sleep apnea and kidney disease, she noted. "These findings highlight the need for continued research to ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.

Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

If you're considering weight loss medications like the popular GLP-1 agonists — like semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) — you're probably wondering whether your ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.